Potential biomarker to predict acute kidney injury earlier than current tests

Clinicians currently lack advance warning of acute kidney injury (AKI) for patients where kidney injury timing is unknown.

Now paediatric research published in the open access journal, Critical Care, has identified a potential biomarker to predict AKI earlier than current tests, opening a vital window for prevention of this life-threatening condition.

A US team led by Michael Zappitelli, Kimberly Washburn and Stuart Goldstein from Baylor College of Medicine/Texas Children's Hospital in Houston studied urinary neutrophil gelatinase associated lipocalin (uNGAL) levels in a prospective cohort of 140 critically ill children. They found that uNGAL was a good diagnostic marker for AKI development, with levels at least 6 times higher than control subjects.

The rise in uNGAL concentration occurred 48 hours before a jump in serum creatinine (SCr) levels. This is significant because SCr, currently the main AKI biomarker used in clinical settings, shows a reduction in renal function has already begun and even small SCr rises are independently associated with mortality. The authors suggest that uNGAL is a good diagnostic marker for early prediction of AKI when the timing of the kidney injury is unknown. However, they caution that urinary NGAL may not be a good predictor of AKI severity after a jump in SCr has occurred.

The authors found that children in the study with sepsis have higher uNGAL concentrations than those without sepsis, but the relationship between uNGAL and AKI was maintained. "The ultimate goal will be to have a biomarker panel in a urine dipstick format to rapidly assess biomarker threshold concentrations," Zappitelli says. It remains to be seen whether the results will be duplicated in adults, in whom a higher degree of chronic inflammation may also affect uNGAL levels.

http://www.biomedcentral.com

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Semaglutide reduces urine albumin-to-creatinine ratio in overweight chronic kidney disease patients